If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus. 1 sitaGLIPtin (sit-a-glip-tin) Januvia Classification Therapeutic:antidiabetics Pharmacologic:enzymeinhibitors ... 2015 F.A. A1 - Quiring,Courtney, CAPITALS indicate life-threatening, underlines indicate most frequent. Davis's Drug Guide for Rehabilitation Professionalshttps://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139025979https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139025979https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139025979. Davis Company AU - Vallerand,April Hazard, AU - Sanoski,Cynthia A,

Davis Company Nursing Central is an award-winning, complete mobile solution for nurses and students. ��-.n��C��������_����ՁS�rqq˓Jdq����_s� ۽N���� �J��vv����b�)(����@fwKHE����.������ �ƱR���t�at����hM;�(�

Access up-to-date medical information for less than $2 a weekQuiring, C., Sanoski, C. A., & Vallerand, A. H. (2020). T1 - SITagliptin

AU - Vallerand,April Hazard, ID - 109219 Strikethrough Discontinued. Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. JANUVIA should not be used in patients with type 1 diabetes or with diabetic ketoacidosis (increased ketones in the blood or urine). Davis Drug Guide PDF. Report severe or prolonged symptoms to the physician.Implement aerobic exercise and endurance training programs to maintain optimal body weight, improve insulin sensitivity, and reduce the risk of macrovascular disease (heart attack, stroke) and microvascular problems (reduced blood flow to tissues and organs that causes poor wound healing, neuropathy, retinopathy, and nephropathy).Encourage patient to monitor blood glucose before and after exercise and to adjust food intake to maintain normal glycemic levels.Emphasize the importance of adhering to nutritional guidelines and the need for periodic assessment of glycemic control (serum glucose and glycosylated hemoglobin levels) throughout the management of diabetes mellitus.Advise patient about symptoms of hyperglycemia (confusion, drowsiness; flushed, dry skin; fruit-like breath odor; rapid, deep breathing, polyuria; loss of appetite; unusual thirst). UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109219/all/sitaGLIPtin ��R@��`le�q��E��� �C�"�����s��G i�.V�j�8���>j]�V��[�y�1�}� yf����Eq�`1��;8� stream %��������� �ϸ�����O���J�^\�(��ⳅ�R�=�+|����(���72�R�K��w}w�@C��.�l�M�݉U^��z�@�p���}��i�a_9 �}�%�htz�Ω�%������, -2���&�듩Ȁގ� �#���נ�.>��m�V���/�{W�b�|{�V����rrC���K��axo�� �}\��+CH��~����}���LK�o�v;jxC0I�f�$ԕ�K.sy���? Please consult the latest official manual style if you have any questions regarding the format accuracy.Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus; may be used as monotherapy or combination therapy with metformin and a thiazolidinedione and/or a sulfonylurea.Inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which slows the inactivation of incretin hormones, resulting in increased levels of active incretin hormones. Please Sign in with your Harriet Lane Handbook accountType your tag names separated by a space and hit enterThe Harriet Lane Handbook app and website provides pediatric diagnosis and treatment, pediatric management algorithms, and pediatric drug formulary from experts at Johns Hopkins University. SITagliptin. Title: linagliptin.1_2.pdf Created Date: 2/18/2014 7:01:24 AM ER -